Physician

Afrouz S. Gerayli, MD

According to 2025 Medicare claims, Afrouz Gerayli, MD (NPI: 1801044839) practices internal medicine in the Oxnard-Thousand Oaks-Ventura, CA market, with the plurality of this provider's patient population coming from Ventura, CA. This provider's primary affiliated billing organization is AFROUZ GERAYLI MD INC (NPI: 1295828259; TIN: 922567794) and primary practice location at 93010-5900.

Gerayli's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 865 traditional Medicare patients, billed 21,230 HCPCS/CPT codes, and received $1,110,836 in Medicare payments. The top billing code was G0439 (Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit). Part D data shows 16,064 prescription claims across 919 beneficiaries totaling $2,139,221 in drug costs, led by Ozempic (Semaglutide). DME data shows 263 claims. Open Payments data shows 55 records totaling $1,511. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $463,367 to $1,110,836. Similarly, Part D prescription costs have moved sharply higher in recent years, from $706,042 to $2,139,221. In contrast, DME billing represents a smaller volume and moved from a lower plateau to a higher plateau, from $12,948 to $36,214.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	814	7,701	$463,367
2016	834	8,249	$478,843
2017	836	9,476	$542,062
2018	817	9,588	$537,181
2019	774	9,557	$567,937
2020	764	9,778	$580,762
2021	788	9,499	$644,423
2022	824	10,209	$700,580
2023	846	12,693	$784,279
2024	865	21,230	$1,110,836

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	620	11,333	$706,042
2016	650	11,832	$797,276
2017	684	12,505	$833,921
2018	687	11,979	$866,212
2019	696	12,588	$1,072,285
2020	704	12,773	$1,229,107
2021	768	12,898	$1,522,916
2022	840	13,652	$1,956,426
2023	855	14,945	$2,040,120
2024	919	16,064	$2,139,221

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	80	462	$9,358
2016	114	343	$6,130
2017	68	412	$7,402
2018	82	377	$15,369
2019	61	312	$20,526
2020	64	330	$26,627
2021	58	411	$43,655
2022	32	361	$31,385
2023	32	258	$23,205
2024	16	263	$28,129

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
G0439	Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit	609	609	$139
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	718	1,829	$94
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	685	2,095	$64
99457	Management using the results of remote vital sign monitoring per calendar month, first 20 minutes	449	3,385	$42
G0442	Annual alcohol misuse screening, 5 to 15 minutes	663	663	$21

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Ozempic	Semaglutide	249	9,102	$279,615
Mounjaro	Tirzepatide	222	6,712	$239,615
Farxiga	Dapagliflozin Propanediol	178	12,150	$217,802
Jardiance	Empagliflozin	147	8,795	$169,601
Eliquis	Apixaban	155	7,818	$145,820

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
A4239	Supply allowance for non-adjunctive, non-implanted continuous glucose monitor (cgm), includes all supplies and accessories, 1 month supply = 1 unit of service	N	N/R	59	$22,836
E1390	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate	Y	N/R	12	$944
A4604	Tubing with integrated heating element for use with positive airway pressure device	N	N/R	24	$887
A7034	Nasal interface (mask or cannula type) used with positive airway pressure device, with or without head strap	N	N/R	17	$825
E0260	Hospital bed, semi-electric (head and foot adjustment), with any type side rails, with mattress	Y	N/R	16	$740

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	55	$1,511	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Afrouz S. Gerayli, MD?

Tedicare shows public-source Medicare data for Afrouz S. Gerayli, MD (NPI 1801044839), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Afrouz S. Gerayli, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Afrouz S. Gerayli, MD?

Afrouz S. Gerayli, MD is linked to AFROUZ GERAYLI MD INC (billing NPI 1295828259) in the available physician profile data.

Does Afrouz S. Gerayli, MD have Open Payments data?

Afrouz S. Gerayli, MD has 55 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.